Akston Biosciences' AKS-107 Study Published in Frontiers in Immunology, Displaying Ambifect® Platform’s Versatility

BEVERLY, Mass.–(BUSINESS WIRE)– #AKS107–Akston Biosciences’ AKS-107 Study published in Frontiers in Immunology, validates Ambifect® Platform’s versatility across diverse treatment areas.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks